Literature DB >> 11518688

Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release.

F Y Enç1, N Imeryüz, L Akin, T Turoğlu, F Dede, G Haklar, N Tekeşin, N Bekiroğlu, B C Yeğen, J F Rehfeld, J J Holst, N B Ulusoy.   

Abstract

We investigated the effect of acarbose, an alpha-glucosidase and pancreatic alpha-amylase inhibitor, on gastric emptying of solid meals of varying nutrient composition and plasma responses of gut hormones. Gastric emptying was determined with scintigraphy in healthy subjects, and all studies were performed with and without 100 mg of acarbose, in random order, at least 1 wk apart. Acarbose did not alter the emptying of a carbohydrate-free meal, but it delayed emptying of a mixed meal and a carbohydrate-free meal given 2 h after sucrose ingestion. In meal groups with carbohydrates, acarbose attenuated responses of plasma insulin and glucose-dependent insulinotropic polypeptide (GIP) while augmenting responses of CCK, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY). With mixed meal + acarbose, area under the curve (AUC) of gastric emptying was positively correlated with integrated plasma response of GLP-1 (r = 0.68, P < 0.02). With the carbohydrate-free meal after sucrose and acarbose ingestion, AUC of gastric emptying was negatively correlated with integrated plasma response of GIP, implying that prior alteration of carbohydrate absorption modifies gastric emptying of a meal. The results demonstrate that acarbose delays gastric emptying of solid meals and augments release of CCK, GLP-1, and PYY mainly by retarding/inhibiting carbohydrate absorption. Augmented GLP-1 release by acarbose appears to play a major role in the inhibition of gastric emptying of a mixed meal, whereas CCK and PYY may have contributory roles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518688     DOI: 10.1152/ajpgi.2001.281.3.G752

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  27 in total

1.  Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels.

Authors:  Juan Patricio Valderas; Jessica Ahuad; Lorena Rubio; Manuel Escalona; Felipe Pollak; Alberto Maiz
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

2.  Characterization and functional role of voltage gated cation conductances in the glucagon-like peptide-1 secreting GLUTag cell line.

Authors:  F Reimann; M Maziarz; G Flock; A M Habib; D J Drucker; F M Gribble
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 3.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 4.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

5.  Incretin secretion in humans is under the influence of cannabinoid receptors.

Authors:  Chee W Chia; Olga D Carlson; David D Liu; Isabel González-Mariscal; Sara Santa-Cruz Calvo; Josephine M Egan
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-06-27       Impact factor: 4.310

Review 6.  A review of the efficacy and safety of oral antidiabetic drugs.

Authors:  Stephanie Aleskow Stein; Elizabeth Mary Lamos; Stephen N Davis
Journal:  Expert Opin Drug Saf       Date:  2012-12-14       Impact factor: 4.250

7.  Carbohydrates designed with different digestion rates modulate gastric emptying response in rats.

Authors:  Like Y Hasek; Robert J Phillips; Anna M R Hayes; Kimberly Kinzig; Genyi Zhang; Terry L Powley; Bruce R Hamaker
Journal:  Int J Food Sci Nutr       Date:  2020-03-11       Impact factor: 3.833

Review 8.  New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Authors:  Angela M Abbatecola; Stefania Maggi; Giuseppe Paolisso
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.

Authors:  Yan Yang; Alexander A Moghadam; Zachary A Cordner; Nu-Chu Liang; Timothy H Moran
Journal:  Endocrinology       Date:  2014-06-20       Impact factor: 4.736

Review 10.  Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?

Authors:  Guillaume Charpentier; Jean-Pierre Riveline; Dured Dardari; Michel Varroud-Vial
Journal:  Drugs       Date:  2006       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.